EMA Prepares For Launch Of PRIME Priority Medicines Scheme

This article was originally published in SRA

01 Mar 2016
News

Ian Schofield @ScripIanS ian.schofield@informa.com

Executive Summary

On March 7, the European Medicines Agency is to launch its keenly awaited PRIME (priority medicines) scheme, which is intended to support the development of medicines for patients with no treatment options or that offer a major advantage over existing drugs.

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

Topics

Industries
BioPharmaceutical
Regions
Europe
Subjects
Regulation

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

BioPharmaceutical Europe Regulation

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS079194

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS079194

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

EMA Prepares For Launch Of PRIME Priority Medicines Scheme

News

Executive Summary

Related Content

'Different Animals With Different Purposes': Putting PRIME And Adaptive Pathways In Context

Topics

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert